White House COVID-19 response coordinator Dr. Ashish Jha said on May 22 he expects a U.S. Food and Drug Administration decision on authorizing Moderna’s vaccine for children under age five within the next few weeks.
Health officials are considering extending the eligibility for a second COVID-19 vaccine booster dose to people under 50 amid a steady rise in cases, with the United States seeing a threefold increase over the past month.
Rising COVID-19 cases are driving up the use of therapeutics, with Pfizer Inc.’s oral antiviral treatment Paxlovid seeing a 315 percent jump over the past four weeks, U.S. health officials said on May 17.
The United States will allow baby formula imports from foreign makers that do not usually sell their products here, the Food and Drug Administration said on May 16, as it tries to ease a nationwide shortage that has left parents scrambling to feed their babies.
The White House is preparing for a scenario in which Congress fails to approve President Joe Biden’s request for additional COVID funds by reviewing old contracts to see if there is any money it can “claw back,” the president’s top COVID adviser said on May 12.
President Joe Biden on May 12 commemorated the death of 1 million people in the United States from COVID-19, marking what he called “a tragic milestone” and urging Americans to “remain vigilant” amid the ongoing pandemic.
ReutersU.S. President Joe Biden’s administration is aiming to expand access to COVID-19 oral antiviral treatments like Pfizer Inc.’s Paxlovid by doubling the number of locations at which they are available, the White House said on April 26.
ReutersA second Global COVID-19 Summit will be held virtually during May for countries to discuss efforts to end the pandemic and prepare for future health threats, according to a joint statement on April 18.
The Biden administration on Wednesday launched a new website to provide a clearinghouse of information on COVID-19 as part of a continuing effort to prepare Americans to live with the coronavirus.
While Moderna and Pfizer-BioNTech have submitted Emergency Use Authorization (EUA) requests for their COVID-19 vaccines, the data so far suggest the benefits of a fourth shot may be modest.